H.C. Wainwright Maintains Scilex Holding(SCLX.US) With Buy Rating, Cuts Target Price to $7
H.C. Wainwright analyst Ram Selvaraju maintains $Scilex Holding(SCLX.US)$ with a buy rating, and adjusts the target price from $8 to $7.According to TipRanks data, the analyst has a success rate of 37
Express News | Scilex Holding Company : H.c. Wainwright Cuts Target Price to $7 From $8
With Scilex Holding Up 36%, Insider Buyers Count Their Returns
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.
Scilex Holding(SCLX.US) Director Buys US$51,640.75 in Common Stock
$Scilex Holding(SCLX.US)$ Director Chun Jay purchased 57,500 shares of common stock on May 17, 2024 at an average price of $0.8981 for a total value of $51,640.75.Source: Announcement What is statemen
Scilex Holding(SCLX.US) Officer Buys US$43,985 in Common Stock
$Scilex Holding(SCLX.US)$ Officer Ji Henry purchased 50,000 shares of common stock on May 17, 2024 at an average price of $0.8797 for a total value of $43,985.Source: Announcement What is statement of
Scilex Holding(SCLX.US) Officer Buys US$121.95K in Common Stock
$Scilex Holding(SCLX.US)$ Officer SHAH JAISIM purchased 140K shares of common stock on May 16, 17, 2024 at an average price of $0.871 for a total value of $121.95K.Source: Announcement What is stateme
Scilex Holding(SCLX.US) Officer Buys US$12,443.2 in Common Stock
$Scilex Holding(SCLX.US)$ Officer Ma Stephen Hoi purchased 14,140 shares of common stock on May 17, 2024 at an average price of $0.88 for a total value of $12,443.2.Source: Announcement What is statem
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
Positive Sentiment Still Eludes Scilex Holding Company (NASDAQ:SCLX) Following 39% Share Price Slump
To the annoyance of some shareholders, Scilex Holding Company (NASDAQ:SCLX) shares are down a considerable 39% in the last month, which continues a horrid run for the company.
10-Q: Quarterly report
Scilex Provides Information To Stockholders Regarding Manipulative And Naked Short Selling Of Its Common Stock
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
Scilex Holding Is Maintained at Buy by HC Wainwright & Co.
Scilex Holding Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Scilex Holding (SCLX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $8.00.
HC Wainwright & Co. : The Scilex Holding (SCLX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $8.00.
HC Wainwright & Co. Maintains Buy on Scilex Holding, Lowers Price Target to $8
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Scilex Holding (NASDAQ:SCLX) with a Buy and lowers the price target from $12 to $8.
Scilex Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 831.15% HC Wainwright & Co. $12 → $8 Maintains Buy 12/04/2023 1296.73% HC Wainwright & Co. → $1
Scilex Falls on Direct Offering to Raise $15M
Scilex Holding Company Announces $15M Registered Direct Offering Of 15M Shares At $1.00/Share
Scilex Holding Company Announces $15M Registered Direct Offering Of 15M Shares At $1.00/Share
Scilex Issues Preliminary Q1 Sales Results for ZTlido
Scilex Holding (SCLX) said Tuesday that Q1 net sales of ZTlido are expected to be between $12 million and $13 million, compared with $10.6 million in Q1 2023. The company also said that it plans to re
Scilex to Reduce R&D Expenses in 2024, Comments on Actions Post Change Healthcare Cyberattack